Precision Lung Cancer Survivorship Care Intervention

Lung Cancer Clinical Trial

— KYLEADSII  

Official title:

Precision Lung Cancer Survivorship Care Intervention: A Randomized Controlled Trial Serving Rural Survivors and Communities

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT05857995
• Other study ID #: 23-1029.cc
• Secondary ID: R01CA254734
• Status: Not yet recruiting
• Phase: N/A
• Start date: June 1, 2024
• Est. completion date: June 30, 2027

Study information

• Verified date: May 2024
• Source: University of Colorado, Denver
• Contact: Kaitlyn Hoover, MS
• Phone: (770) 238-7144
• Email: kaitlyn.hoover[@]cuanschutz.edu
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The overarching goal of the Kentucky LEADS Collaborative Lung Cancer Survivorship Care program is to reduce the burden of lung cancer by offering an innovative survivorship care approach that improves lung cancer quality of life, overcomes lung cancer stigma, and helps survivors engage with care. The project involves a two-group parallel randomized clinical trial comparing the impact of the Kentucky LEADS Collaborative Lung Cancer Survivorship Care program (KLCLCSC) among lung cancer survivors (N=300) against an enhanced usual care condition (bibliotherapy+assessment) on quality of life outcomes.

Description:

Among the devastating illnesses impacting rural America, few exact the physical, social, psychological, and economic toll of lung cancer. Lung cancer is the leading cause of cancer death in rural America, and the levy is particularly acute in Kentucky - a state that not only leads the nation in lung cancer incidence and mortality but is a global epicenter of lung cancer. Despite the prevailing nihilism regarding lung cancer care, lung cancer survivors are living longer. Innovations in prevention, early detection, and treatment, have created substantial optimism and opportunities for long-term lung cancer survivorship. These dramatic changes in the lung cancer care landscape have invigorated the need for quality lung cancer survivorship interventions. The overarching goal of the Kentucky LEADS Collaborative Lung Cancer Survivorship Care program is to reduce the burden of lung cancer by offering an innovative survivorship care approach that improves lung cancer quality of life, overcomes lung cancer stigma, and helps survivors engage with care. Using a novel precision survivorship approach and developed in collaboration with rural community stakeholders, the program's foundation incorporates principles of patient-centered care, shared decision making, and motivational interviewing to build survivor engagement. A large acceptability and feasibility trial conducted in collaboration with nine lung cancer care facilities in Kentucky with lung cancer survivors (N=140) demonstrated the acceptability of the intervention among survivors, caregivers, and lung cancer care clinicians. The study also revealed the feasibility of conducting the proposed study methods in rural cancer care facilities. The project continues this program of research by conducting a two-group parallel randomized clinical trial comparing the impact of the Kentucky LEADS Collaborative Lung Cancer Survivorship Care program (KLCLCSC) among lung cancer survivors (N=300) against an enhanced usual care condition (bibliotherapy+assessment) on quality of life outcomes. Rural-residing lung cancer survivors will be recruited from ten oncology care facilities throughout Kentucky. The project's first aim compares the efficacy of the interventions with regard to lung cancer quality of life among survivors as measured by the FACT-L and other rigorous assessments of patient engagement, symptom burden, psychosocial well-being, and behavior change. The project's second aim evaluates the moderating impact of including caregivers as intervention partners on survivor quality of life outcomes. A third aim evaluates the cost-effectiveness of the KLCLCSC intervention in comparison to the enhanced usual care condition. Based on highly encouraging pilot data collected in collaboration with oncology care programs in Kentucky, this research holds credible potential to establish a new paradigm for addressing the challenges associated with lung cancer and for delivering quality survivorship care to rural-residing, economically distressed lung cancer survivors.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 300
• Est. completion date: June 30, 2027
• Est. primary completion date: March 31, 2027
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Have been diagnosed with lung cancer

• Reside in a rural county as determined by a RUC code of 4 or higher

• Be at least 18 years of age or older

• Be able to communicate effectively in English

Exclusion Criteria:

• Have significant psychiatric disturbance that requires a higher level of care

• Have substance abuse/dependence that requires a higher level of care

• Are participating in another lung cancer survivorship care intervention

• Have previously participated in the Kentucky LEADS Lung Cancer Survivorship Care Program

Related Conditions & MeSH terms

• Cancer of Lung
• Cancer of the Lung
• Cancer, Lung
• Lung Cancer
• Lung Cancers
• Lung Neoplasms
• Neoplasms
• Neoplasms, Lung
• Neoplasms, Pulmonary
• Pulmonary Cancer
• Pulmonary Neoplasm
• Pulmonary Neoplasms

Intervention

Behavioral:
• Kentucky LEADS Collaborative Lung Cancer Survivorship Care Program
KLCLCSC is a survivor or survivor plus caregiver-focused psychosocial and behavioral intervention designed to engage lung cancer survivors and improve lung cancer outcomes.
• Enhanced Usual Care
EUC involves a combination of the standard of care plus a bibliotherapy intervention and assessment.

Locations

Country	Name	City	State
n/a

Sponsors (5)

Lead Sponsor	Collaborator
University of Colorado, Denver	G02 for Lung Cancer, National Cancer Institute (NCI), University of Kentucky, University of Louisville

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change from Baseline (T0) in Mean Lung Cancer Quality of Life at 6 Months (T2)	The Functional Assessment of Cancer Therapy-Lung (FACT-L) is a 36-item self-report instrument that measures quality life. Scores range from 0 to 144 with higher scores indicating better quality of life.	Baseline (T0) and 6 Months (T2)
Secondary	Change from Baseline (T0) in Total Survivor Engagement at 6 Months (T2)	The Patient Activation Measure (PAM) is a standardized 13-item self-report measure of patient engagement with a theoretical range of 0 to 100 with higher scores indicating greater engagement.	Baseline (T0) and 6 Months (T2)
Secondary	Change from Baseline (T0) in Mean Lung Cancer Knowledge at 6 Months (T2)	The Perceived Knowledge of Lung Cancer Scale is a 6-item intervention-specific measure of self-reported/perceived knowledge of lung cancer and survivorship developed for this research program. Scores range from 0 to 24 with higher scores indicating greater knowledge.	Baseline (T0) and 6 Months (T2)
Secondary	Change from Baseline (T0) in Mean Fatigue Symptoms at 6 Months (T2)	Fatigue Symptoms is a standardized 5-item self-report measure of fatigue within the Patient-Reported Outcomes Measurement Information System (PROMIS-Fatigue). Scores range from 0 to 20 with higher scores indicating better quality of life and lesser fatigue symptoms.	Baseline (T0) and 6 Months (T2)
Secondary	Change from Baseline (T0) in Mean Sleep Disturbance at 6 Months (T2)	Sleep Disturbance is a standardized 6-item self-report measure of sleep disruption within the Patient-Reported Outcomes Measurement Information System (PROMIS-Sleep). Scores range from 0 to 20 with higher scores indicating better quality of life and lesser seep disturbance.	Baseline (T0) and 6 Months (T2)
Secondary	Change from Baseline (T0) in Pulmonary Symptoms at 6 Months (T2)	Respiratory Dysfunction (FACT-L Pulmonary Symptom Index) is a 4-item self-report measure of breathing problems drawn from the Functional Assessment of Cancer Therapy Lung Cancer Module. Scores range from 0 to 16 with higher scores indicating better quality of life and lower pulmonary symptoms.	Baseline (T0) and 6 Months (T2)
Secondary	Change from Baseline (T0) in Mean Pain Interference at 6 Months (T2)	Pain Interference is a standardized 6-item self-report measure of pain interference within the Patient-Reported Outcomes Measurement Information System (PROMIS-Pain). Scores range from 0 to 24 with higher scores indicating better quality of life and lesser pain interference.	Baseline (T0) and 6 Months (T2)
Secondary	Change from Baseline (T0) in Mean Emotional Social Support at 6 Months (T2)	Emotional Social Support is a standardized 4-item self-report measure of emotional social support within the Patient-Reported Outcomes Measurement Information System (PROMIS-Emotional Support). Scores range from 0 to 16 with higher scores indicating better quality of life and greater emotional social support.	Baseline (T0) and 6 Months (T2)
Secondary	Change from Baseline (T0) in Mean Knowledge of Palliative Care at 6 Months (T2)	The Knowledge of Palliative Care (Perceptions) scale is a standardized 4-item self-report measure of knowledge about palliative care. Scores range from 4 to 16 with higher scores indicating greater self-rated knowledge of palliative care.	Baseline (T0) and 6 Months (T2)
Secondary	Change from Baseline (T0) in Psychological Distress at 6 Months (T2)	The Distress Thermometer is an ultra-brief, single-item, standardized self-report measure of psychological distress developed and supported by the National Comprehensive Cancer Network (DT) with higher scores indicating greater distress (Range = 0 to 10).	Baseline (T0) and 6 Months (T2)
Secondary	Change from Baseline (T0) in Mean Physical Activity at 6 Months (T2)	The Godin Leisure-Time Exercise Questionnaire includes 3 standardized self-report items assessing levels of strenuous, moderate, and mild/light physical activity. Scores are based on weekly activities with zero being the lowest score and higher scores indicating more frequent and strenuous physical activity.	Baseline (T0) and 6 Months (T2)
Secondary	Change from Baseline (T0) in Smoking Status at 6 Months (T2)	The Smoking Status (BRFSS-Tobacco Use) measure is a single-item standardized self-report measure of 30-day smoking point prevalence. Scores range from 0 to 1 with 1 indicating current smoking.	Baseline (T0) and 6 Months (T2)
Secondary	Change from Baseline (T0) in Lung Cancer Stigma at 6 Months (T2)	The Lung Cancer Stigma Inventory - Short Form includes 12 self-report items measuring lung cancer stigma. Scores range from 12 to 60 with higher scores indicating greater lung cancer stigma.	Baseline (T0) and 6 Months (T2)